02011nas a2200325   4500000000100000008004100001260001700042653001500059653001000074653001100084653001000095653002100105653001800126653002000144653001100164653002200175653001200197653001300209653001600222100001700238700001700255700001400272245006900286856004800355300001100403490000700414050001800421520123200439022001401671       1999                            d  c1999 Jan-Mar10aAdolescent10aAdult10aBrazil10aChild10aChild, Preschool10aDrug Approval10aDrug Monitoring10aHumans10aLegislation, Drug10aleprosy10aSyndrome10aThalidomide1 aOliveira M A1 aBermudez J A1 aSouza A C00a[Thalidomide in Brazil: monitoring with shared responsibility?].  uhttp://www.scielo.br/pdf/csp/v15n1/0040.pdf  a99-1120 v15  aOLIVEIRA 19993 a<p>This paper discusses issues related to the regulation and rational use of thalidomide in Brazil, by means of a historical approach comprising three different stages. The first part is a historical review of the controversial drug since it was first synthesized, then marketed and subsequently banned during the 1950s and 60s, until the present, when an apparently irreversible process of rehabilitating the drug is under way. Brazilian experience with the use of thalidomide is described, emphasizing legal, political, and institutional work led by two social movements, the Brazilian Association of People with Thalidomide Syndrome (ABPST) and the Movement for Reintegration of People with Hansen's Disease (Morhan). The article describes the results and analyzes an active search of new cases in what is a second generation of thalidomide syndrome in Brazil. Finally, based on clinical and scientific evidence of thalidomide's therapeutic efficacy, the growth of social movements struggling both for and against authorization of the drug, and a restrictive regulation proposed by the Ministry of Health, the article discusses the implementation of policies for the regulation and rational use of thalidomide in Brazil.</p>  a0102-311X